Optimal Sequencing of Pembrolizumab (MK-3475) and Standard Platinum-based Chemotherapy in First-Line NSCLC

NCT02591615 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

91

Enrollment

OTHER

Sponsor class

Conditions

Non-Small Cell Lung Cancer

Interventions

DRUG: MK-3475
DRUG: Carboplatin
DRUG: Paclitaxel
DRUG: Pemetrexed

Sponsor

Alliance Foundation Trials, LLC.

Collaborators

[object Object]